Valeo Pharma Inc (VPHIF) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good evening, this is the conference operator. Welcome and thank you for joining the Valeo first quarter 2026 phase conference call and webcast. As a reminder, all participants are in listen-only mode. After the presentation there will be an opportunity to ask questions. Please note that we will only take two questions per person. Should anyone need assistance during the conference call, They may signal an operator by pressing star and zero on their telephone. At this time, I would like to turn the conference over to Ms. Marisa Baldeau, VP Financial Communication and Investor Relations of Valeo. Please go ahead, madam. Good evening, everyone, and welcome to Valeo's first quarter self-conference phone. I'm Marisa Baldeau, and joining me is our CFO, Edouard de Thierry. The format for today will be a presentation for 10 to 15 minutes, followed by a Q&A session for sales side analysts. For your reference, the press releases and slides are already available on our website at www.baleo.com. A replay of the call will also be available on our website. Before Edouard begins, I want to quickly direct you Director attention to the disclaimer on slide 19 which I invite everyone to read. Thank you again for joining us. Edouard, the floor is now yours. Thank you, thank you very much Marisa and good evening to all and thank you for joining Valeo's first quarter 2026 sales presentation. So let's start with the key takeaways for the quarter on slide 2. In a global environment that remains volatile, who delivered a solid performance. Total sales were up 1.3% on the like-for-like basis, consistent with our four-year objective. OEM sales decreased slightly like-for-like in a market down by 3%, resulting in a three-point outperformance. All three divisions outperformed. The execution of ...